Commentary
by
Pytell, Jarratt D. & Darious A. Rastegar
Release Date
2020
Geography
USA
Language of Resource
English
Full Text Available
Yes
Open Access / OK to Reproduce
Yes
Peer Reviewed
Unknown
Objective
We discuss how COVID-19 has ended the practice of “routine” UDT in office-based opioid treatment (OBOT), encouraged a more patient-centered approach, and why targeted, as opposed to routine, UDT should be a lesson learned for practitioners from this pandemic
Findings/Key points
Routine UDS is costly, has environmental implications, may cause harms when results dictate treatment decisions, may case long-term stable patients to feel untrusted. Targeted UDT is helpful when evaluating a patient who is exhibiting potentially toxic effects of an unknown substance, to help guide treatment initiation for opioid agonist or antagonist therapy, or for those patients who want or would benefit from the positive reinforcement of UDT.
Keywords
Evidence base
Policy/Regulatory
About prescribers
